SUBSCribe
logo
twitterlinkedininstagramUser Profile
  • BIG STORY
  • PERSPECTIVE
    • Editor's Note
  • ENTERPRISE
    • STRATEGY
      • HIGH FIVE
      • AD Break
    • MARKETS
      • PIXTORY
        • SPECIALS
        • VIDEOS
        • WOMEN
        • C’est La Vie
          • My Favourite
          • Pursuit of Happiness
          • The Good Life
          • Hardbound
        • MAGAZINE
        • EVENTS
          • LEADING EDGE
          • SMART ENTERPRISE
        • What is your top priority for next year?

          With a digital-first focus, India Inc’s top bosses are gearing up for an action-packed 2021 

          Krishna Gopalan - December 04, 2020
        • What does Rakesh Jhunjhunwala see in Jubilant Life Sciences?

          Within a year, the investing legend has doubled down on his latest pharma bet

          Himanshu Kakkar - May 23, 2020
        • New growth model

          Indian pharma majors are facing their toughest year yet in the US, with regulatory clampdown, hostile political environment and falling prices. Is reinvention the answer to their woes?

          Kripa Mahalingam - July 26, 2019
        • Tricky Transition

          Generic Indian pharma players are changing their formula to focus on high-margin complex generics and specialty drugs

          N Mahalakshmi - July 16, 2019
        • Growth Inhibitor

          In Ankleshwar, feisty MSMEs that survived the Chinese onslaught say that the fight against red tapism is harder

          Krishna Gopalan - January 25, 2019
        • Injecting Growth

          By focusing on its strength in manufacturing lyophilized injectables, Gufic Biosciences has made a strong comeback and wants to aggressively push into the EU market next

          Jash Kriplani - April 16, 2018
        • Nursing Back to Health

          A strong product pipeline and receding US FDA threat could well turn the tide in favour of the beleaguered pharma players

          Jash Kriplani - October 18, 2017
        • The Comeback Plan

          Lupin is betting on its specialty drugs business to counter the pricing pressures in the US generics market 

          Khushboo Balani - October 03, 2017
        • Ajay Relan

          His bet on Natco Pharma’s differentiated product portfolio paid off while Monnet Ispat taught him to be wary of over-ambitious entrepreneurs

          Krishna Gopalan - September 18, 2017
        • Going all-in

          Why Star paid top dollar for India's premier domestic tourney

          N Mahalakshmi - September 29, 2017